Download Library

 
 
 
Download Library
Document Type
Articles of Association dated November 14, 2017
pdf
334.0 KB
Jefferies London Healthcare Conference, London, UK
PDF
2.4 MB
Q3 2017 Results Podcast
MP3
29.1 MB
Genmab First Nine Months of 2017 Results Presentation
PDF
792.8 KB
Interim Report for the First Nine Months of 2017
pdf
589.5 KB
A Phase IIa Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Relapsed, Recurrent and/or Metastatic Cervical Cancer: Updated Safety and Efficacy - ESGO E-poster - November 2017 (Concin)
PDF
453.8 KB
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy & Safety Analysis of POLLUX - ASH abstract - November 2017 (Dimopoulos)
URL
N/A
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone for Relapsed / Refractory Multiple Myeloma Patients: An Update of Overall Survival in CASTOR - ASH abstract - November 2017 (Lentzsch)
URL
N/A
Interim Safety Analysis of a Phase II Randomized Study of Daratumumab, Lenalidomide, Bortezomib and Dexamethasone vs Lenalidomide, Bortezomib and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for HDT and ASCT- ASH abstract -November 2017 (Voorhees)
URL
N/A
Safety and Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed and Refractory Multiple Myeloma: Final Results from GEN501 and SIRIUS - ASH abstract - November 2017 (Usmani)
URL
N/A
Daratumumab Monotherapy for Patients with Intermediate or High-risk Smoldering Multiple Myeloma: CENTAURUS - ASH abstract - November 2017 (Hofmeister)
URL
N/A
Daratumumab, Lenalidomide and Dexamethasone vs Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Based on Prior Treatment History, Renal Function, and Cytogenetic Risk: Subgroup Analyses of POLLUX - ASH abstract - November 2017 (Moreau)
URL
N/A
Daratumumab in Combination with Carfilzomib and Dexamethasone in Patients with Relapsed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Lonial)
URL
N/A
Results of an Interim Safety Analysis of a Phase II Study of Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone in Previously Untreated and Relapsed Patients with Multiple Myeloma - ASH abstract - November 2017 (Yimer)
URL
N/A
Daratumumab in Combination with Lenalidomide Plus Dexamethasone Results in Persistent Natural Killer Cells with a Distinct Phenotype and Expansion of Effector Memory T-cells in POLLUX - ASH abstract - November 2017 (van de Donk)
URL
N/A
Cost-effectiveness of Daratumumab Plus Lenalidomide Plus Dexamethasone vs Lenalidomide Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the POLLUX Trial - ASH abstract - November 2017 (Maiese)
URL
N/A
Daratumumab in Combination with Lenalidomide and Dexamethaone in Patients with Relapsed or Relapsed / Refractory Multiple Myeloma (GEN503): Final Results - ASH abstract - November 2017 (Plesner)
URL
N/A
Daratumumab in Combination with Pomalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma in Patients with greater than or equal to 2 Prior Lines of Therapy: Updated Analysis of MMY1001 - ASH abstract - November 2017 (Facon)
URL
N/A
Daratumumab in Combination with Carfilzomib, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma (MMY1001) - ASH abstract - November 2017 (Chari)
URL
N/A
Cost-effectiveness of Daratumumab Plus Bortezomib and Dexamethasone Versus Bortezomib Plus Dexamethasone for Treatment of Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy: an Analysis of the CASTOR Trial - ASH abstract - November 2017 (Maiese)
URL
N/A
Subcutaneous Delivery of Daraumumab in Patients with Relapsed or Refractory Multiple Myeloma: PAVO - ASH abstract - November 2017 (Chari)
URL
N/A
Daratumumab, Bortezomib and Dexamethasone vs Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Efficacy and Safety Analysis of CASTOR - ASH abstract - November 2017 (Spencer)
URL
N/A
Efficacy and Safety of Ofatumumab and Bendamustine Followed by Ofatumumab Maintenance in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma After Prior Rituximab - ASH abstract - November 2017 (Kolibaba)
URL
N/A
Investor Presentation, September 2017
PDF
2.6 MB
A Phase I/II Safety Study of Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Solid Tumours - ESMO Poster - September 2017 (Chenard-Poirier)
PDF
958.9 KB

Page:
1
2
3
4
5
...
18
Next Last

 
 
 

Please be advised that additional documents and media, such as fact sheets and conference call webcasts, are available only in English and can be accessed by clicking on the English tab.

 

Download Library
Document Type
Selskabsvedtægter dateret den. 14. november 2017
pdf
404.8 KB
Safety and efficacy of daratumumab-based regimens in elderly patients with RRMM: Subgroup analysis of POLLUX and CASTOR - ASCO abstract - May 2017 (Mateos)
PDF
150.8 KB
Resumé 2016
PDF
2.4 MB
Adjusted Comparisons Suggest Daratumumab Is Associated with Prolonged Survival Compared with Standard of Care in pts with Heavily Pre-Treated & Highly Refractory MM - ASH poster - December 2016 (Kumar)
PDF
530.3 KB
Management of transaminase elevations associated with idelalisib - EHA poster regarding ofatumumab submitted by Gilead - June 2016 (Ghia)
PDF
1.5 MB
Præsentation for Nordnet 30. maj 2016
PDF
1.2 MB
Resumé 2015
PDF
2.6 MB
Selskabsvedtægter dateret den 26. marts 2015
PDF
195.3 KB
Resumé 2014
PDF
1.3 MB
Danish Shareholder Association Event Presentation - September 2014
PDF
822.1 KB
Ordinær generalforsamling 2014 præsentation
PDF
2.6 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2013
URL
N/A
2013 årsrapport
pdf
6.0 MB
Redegørelse for virksomhedsledelse 2013
URL
N/A
Genmab offentliggør resultat for de første ni måneder af 2013
pdf
588.3 KB
Genmab offentliggør resultat for første halvår 2013 og opjusterer forventningerne til 2013
pdf
812.1 KB
Genmab offentliggør resultat for første kvartal 2013
pdf
969.7 KB
Ordinær generalforsamling 2013 præsentation
PDF
1.1 MB
Samfundsansvar (CSR) - Lovpligtig redegørelse for 2012
URL
N/A
Redegørelse for virksomhedsledelse 2012
URL
N/A
2012 årsrapport
pdf
5.7 MB
Genmab offentliggør resultat for de første ni måneder af 2012 og opjusterer forventningerne til 2012
pdf
233.3 KB
Genmab offentliggør resultat for første halvår 2012 og opjusterer forventningerne til 2012
pdf
321.8 KB
Genmab offentliggør resultat for første kvartal 2012
pdf
231.7 KB
Overordnede retningslinjer for incitamentsordninger
PDF
79.0 KB
Page:
1
2
3
4
Next Last